Contact Us
Drug Search Results
More Filters [+]

Idebenone

Alternative Names: idebenone, raxone
Latest Update: 2025-01-07
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Austria | Belgium | Canada | Chile | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Luxembourg | Mexico | Netherlands | Norway | Peru | Poland | Portugal | Romania | Russia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sweden | Turkey | Ukraine | United Kingdom | Uruguay

Approved Indications: None

Known Adverse Events: None

Company: Santhera
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Idebenone

Countries in Clinic: China

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Other

Phase 2: Optic Atrophy, Autosomal Dominant

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
OPA1

P2

Active, not recruiting

Optic Atrophy, Autosomal Dominant

2024-07-21

CTR20220888

P3

Not yet recruiting

Other

None

Recent News Events

Date

Type

Title

10/28/2024

News Article

 GenSight Biologics Announces Publication of Meta-Analyses Showing Better Outcomes for ND4-LHON Patients Treated with LUMEVOQ®

09/12/2024

News Article

 Santhera Announces Half-Year 2024 Financial Results and Provides Corporate Update

04/25/2024

News Article

 Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May

03/12/2024

News Article

 GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions